SEARCH BY

Issuer directory Issuer directory
KEYWORDS
COMPANIES / ISIN
TYPE OF INFORMATION
INDUSTRY

Start search  ADVANCED SEARCH

COMPARTMENTS / INDICES

France
America
Asia
Oceania
Africa
Europe

MSI NEWS

FEEDS

My RSS My Google Microsoft Live My Yahoo

COMPANY SEARCH RESULT

ROCHE: Click to view the issuer\'s details

Last update : 16/08/2018  >View issuer details

2019.03.15 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce European Commission approves Roche's MabThera (rituximab) for a rare autoimmune disease - HTML (w)

2019.03.14 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce European Commission approves Roche's Hemlibra for people with severe haemophilia A without factor VIII inhibitors - HTML (w)

2019.03.07 | 17:35 | Public offerings / Information note / Note in response

English version HTML (w) Mail

puce Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash - HTML (w)

2019.03.05 | 14:23 | Annual General Meeting / Reports

English version HTML (w) Mail

puce Roche Annual General Meeting 2019 - HTML (w)

2019.03.05 | 14:23 | Annual General Meeting / Reports

French version HTML (w) Mail

puce Assemblée générale Roche 2019 - HTML (w)

2019.03.05 | 14:23 | Annual General Meeting / Reports

German version HTML (w) Mail

puce Roche Generalversammlung 2019 - HTML (w)

2019.02.28 | 17:35 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers - HTML (w)

2019.02.25 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce Roche enters into definitive merger agreement to acquire Spark Therapeutics - HTML (w)

2019.02.19 | 07:03 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce FDA grants Priority Review to Roche's personalised medicine entrectinib - HTML (w)

2019.02.19 | 07:00 | Permanent Information Releases / General Company News

English version HTML (w) Mail

puce FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 152